Lilly attempts to revive an old idea for tackling pain, licensing PhI program from Japan’s Asahi Kasei Pharma
Eli Lilly is fronting some new cash in a space they’re quite familiar with.
The company is partnering with Japan’s Asahi Kasei Pharma on an …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
